Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Price Target of $35.33

Key Points

• Analysts broadly favor Odyssey Therapeutics: Ten firms give the stock a consensus “Moderate Buy” rating, with seven buys, one strong buy, one hold, and one sell. The average 12-month price target is $35.33, above the reported $19.83 share price.
• Institutional investors recently established positions, including Citadel Advisors ($4.16 million), State Street ($1.48 million), and Manufacturers Life Insurance ($601,000).
• Odyssey remains a clinical-stage biotechnology company and is unprofitable: it reported quarterly EPS of -$1.74, while analysts expect full-year EPS of approximately -$6.08.

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $35.33.

ODTX has been the topic of several research reports. HC Wainwright began coverage on shares of Odyssey Therapeutics in a research report on Thursday, August 27th. They issued a "buy" rating and a $44.00 price objective on the stock. JPMorgan Chase & Co. raised their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Weiss Ratings initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a "sell (d+)" rating on the stock. Raymond James Financial began coverage on Odyssey Therapeutics in a research note on Thursday, October 8th. They issued an "outperform" rating and a $42.00 price objective on the stock. Finally, UBS Group initiated coverage on Odyssey Therapeutics in a report on Monday, October 12th. They set a "buy" rating and a $27.00 price objective for the company.

Hedge Funds Weigh In On Odyssey Therapeutics

Several large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company bought a new stake in shares of Odyssey Therapeutics in the second quarter valued at approximately $601,000. State Street Corp bought a new position in Odyssey Therapeutics in the 2nd quarter worth approximately $1,477,000. Finally, Citadel Advisors LLC bought a new position in Odyssey Therapeutics in the 2nd quarter worth approximately $4,162,000.

Odyssey Therapeutics Trading Up 1.5%

Shares of Odyssey Therapeutics stock opened at $19.83 on Friday. The stock has a market cap of $953.03 million and a price-to-earnings ratio of -2.93. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05. The company's fifty day simple moving average is $21.90.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, equities analysts forecast that Odyssey Therapeutics will post -6.08 EPS for the current fiscal year.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.